André Scheen

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Diabetes Management, Cardiovascular Disease, Health Policy +10

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Lars Rydén, Peter J. Grant, Stefan D. Anker et al. · European Heart Journal · 2013 · 1.9K citations · Full text

Metabolic Syndrome, Diabetes Management, Diabetes Epidemiology +11

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

Luc F. Van Gaal, Aila Rissanen, André Scheen et al. · The Lancet · 2005 · 1.5K citations · Full text

Obesity, Metabolic Syndrome, Cannabis Use +10

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

André Scheen, Nick Finer, Priscilla Hollander et al. · The Lancet · 2006 · 735 citations · Full text

Obesity, Metabolic Syndrome, Diabetes Management +6